牛牛AI助手已提取核心信息
Shattuck Labs, Inc., a clinical-stage biotechnology company, announced its financial results for the fourth quarter and full year ended December 31, 2023, on February 29, 2024. The company reported a net loss of $17.7 million for the quarter and $87.3 million for the full year. Despite the losses, Shattuck Labs highlighted several positive developments in its clinical trials, including promising data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine for treating Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia patients. The company also completed initial enrollment for Phase 1B dose-expansion cohorts and expects to provide updated data mid-year 2024. Additionally, Shattuck Labs entered into a strategic collaboration with Ono Pharmaceutical to develop novel bifunctional fusion proteins for autoimmune and inflammatory diseases and completed a $50 million offering of common stock and pre-funded warrants, extending its cash runway into 2026. The company's cash and cash equivalents and investments totaled $130.6 million as of December 31, 2023.
Shattuck Labs, Inc., a clinical-stage biotechnology company, announced its financial results for the fourth quarter and full year ended December 31, 2023, on February 29, 2024. The company reported a net loss of $17.7 million for the quarter and $87.3 million for the full year. Despite the losses, Shattuck Labs highlighted several positive developments in its clinical trials, including promising data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine for treating Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia patients. The company also completed initial enrollment for Phase 1B dose-expansion cohorts and expects to provide updated data mid-year 2024. Additionally, Shattuck Labs entered into a strategic collaboration with Ono Pharmaceutical to develop novel bifunctional fusion proteins for autoimmune and inflammatory diseases and completed a $50 million offering of common stock and pre-funded warrants, extending its cash runway into 2026. The company's cash and cash equivalents and investments totaled $130.6 million as of December 31, 2023.
临床阶段的生物技术公司Shattuck Labs, Inc. 于2024年2月29日公布了截至2023年12月31日的第四季度和全年财务业绩。该公司报告本季度净亏损1770万美元，全年净亏损8,730万美元。尽管亏损，Shattuck Labs还是强调了其临床试验的几项积极进展，包括正在进行的 SL-172154 与阿扎西替丁联合用于治疗高风险骨髓增生异常综合征和急性髓系白血病患者的1A/B期临床试验的令人鼓舞的数据。该公司还完成了1B阶段剂量扩张队列的初始注册，并预计将在2024年年中提供最新的数据。此外，Shattuck Labs与小野制药建立了战略合作，开发用于自身免疫和炎症性疾病的新型双功能融合蛋白，并完成了5000万美元的普通股和预先融资认股权证的发行，将其现金流延至2026年。截至2023年12月31日，该公司的现金和现金等价物及投资总额为1.306亿美元。
临床阶段的生物技术公司Shattuck Labs, Inc. 于2024年2月29日公布了截至2023年12月31日的第四季度和全年财务业绩。该公司报告本季度净亏损1770万美元，全年净亏损8,730万美元。尽管亏损，Shattuck Labs还是强调了其临床试验的几项积极进展，包括正在进行的 SL-172154 与阿扎西替丁联合用于治疗高风险骨髓增生异常综合征和急性髓系白血病患者的1A/B期临床试验的令人鼓舞的数据。该公司还完成了1B阶段剂量扩张队列的初始注册，并预计将在2024年年中提供最新的数据。此外，Shattuck Labs与小野制药建立了战略合作，开发用于自身免疫和炎症性疾病的新型双功能融合蛋白，并完成了5000万美元的普通股和预先融资认股权证的发行，将其现金流延至2026年。截至2023年12月31日，该公司的现金和现金等价物及投资总额为1.306亿美元。
有用
没用